PARP Inhibitor Therapy for Prostate Cancer Patients: Emerging Combinations
prostate cancer, PARP Inhibitor Therapy, Poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors, PARP inhibitors, androgen receptor pathway inhibitor (ARPI), homologous recombination repair (HRR) genes, Olaparib plus Radium-223, Olaparib, Radium-223, Niraparib, abiraterone, enzalutamide, Talazoparib, Niraparib plus abiraterone, Talazoparib plus enzalutamide, COMRADE trial, BRCA1/2 alterations, KEYNOTE-365 study, Pembrolizumab, Durvalumab, avelumab, Bipolar Androgen Therapy (BAT), supraphysiologic testosterone (SPT), Cediranib, Olaparib plus Cediranib, Rad3-related protein (ATR) inhibitor, ceralasterib, TRAP trial, KEYLYNK-010 Trial, JAVELIN PARP Medley trial,